The cyclophosphamide equivalent dose as an approach for quantifying alkylating agent exposure: a report from the Childhood Cancer Survivor Study.

Publication Type:

Journal Article


Pediatric blood & cancer, Volume 61, Issue 1, p.53-67 (2014)


2014, Algorithms, Antineoplastic Agents, Alkylating, Area Under Curve, Center-Authored Paper, Clinical Research Division, Cohort Studies, Cyclophosphamide, Female, Humans, June 2014, Male, Pharmacology, PREGNANCY, Public Health Sciences Division, ROC Curve, Survivors


Estimation of the risk of adverse long-term outcomes such as second malignant neoplasms and infertility often requires reproducible quantification of exposures. The method for quantification should be easily utilized and valid across different study populations. The widely used Alkylating Agent Dose (AAD) score is derived from the drug dose distribution of the study population and thus cannot be used for comparisons across populations as each will have a unique distribution of drug doses.